- Forbes•25 minutes ago
Looking at the earnings posted by Merck & Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration
- Investor's Business Daily•2 hours ago
Big U.S. pharmas AbbVie and Merck traded higher and flat, respectively, after reporting positive Q2 results, while France's Sanofi headed lower.
|Bid||42.53 x 400|
|Ask||42.54 x 600|
|52wk Range||37.41 - 54.98|
|Day's Range||41.62 - 42.74|
|Avg Vol (3m)||2,316,758|
As of 3:37 PM EDT. NYSE Real Time Price. Market open.